Explore 3 Stock Ideas & Industry Insights Download Free Report

Nordicus Partners Corporation Common Stock

Company price
2.8 USD -0.13 ( 4.44%)
Last update at 2026-11-20T21:00:00Z
VOLUME
4629
Market Cap
68.45M

Momentum Score

…

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.45
Low
2.87
High
52 Week Price Range
1.48
Low
5.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.93
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-6.52%
Net Debt
0.04M
ROCE
-5.88%
Diluted EPS TTM
-0.22

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Income before tax -4.05M -2.92M -0.30M -8.47M -0.29M
Minority interest 0.05M 0.02M 0.00M - -
Net income -4.00M -2.90M -0.30M -8.47M -0.29M
Selling general administrative 2.76M 1.59M 0.31M 8.48M 0.31M
Reconciled depreciation 0.01M 0.01M 0.00M - -
Operating income -4.37M -2.92M -0.31M -8.48M -0.31M
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.00M -0.00M 0.00M -0.00M 0.00M
Total revenue 0.00M 0.01M 0.00M 0.00M 0.00M
Total operating expenses 4.37M 2.92M 0.31M 8.48M 0.31M
Total other income expense net 0.32M 0.00M 0.01M 0.01M 0.02M
Net income from continuing ops -4.05M -2.92M -0.30M -8.47M -0.29M
Breakdown 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Total assets 75.46M 70.25M 1.81M 0.06M 0.25M
Intangible assets 45.51M 42.71M 0.01M 0.00M -
Other current assets 0.51M 0.04M - 0.00M 0.00M
Total liab 11.23M 10.38M 0.03M 0.03M 0.05M
Total stockholder equity 64.28M 59.87M 1.78M 0.03M 0.19M
Capital stock 0.02M 0.02M 0.00M 0.01M 0.01M
Retained earnings -50.79M -46.78M -43.88M -42.20M -33.73M
Good will 27.16M 25.49M 0.00M - -
Cash 0.02M 0.02M 0.05M 0.01M 0.25M
Total current liabilities 1.17M 1.06M 0.03M 0.03M 0.05M
Net debt 0.04M - - 0.01M -
Short long term debt 0.06M - 0.01M 0.01M -
Total current assets 0.53M 0.06M 0.05M 0.05M 0.25M
Long term investments 2.25M 1.93M 1.75M 0.00M -
Net receivables - - 0.00M 0.04M 0.00M
Accounts payable 1.11M 1.06M 0.01M 0.01M 0.05M
Non currrent assets other 0.00M 0.06M - - -
Non current assets total 74.93M 70.19M 1.76M 0.00M 0.00M
Breakdown 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2026-08-31 2025-08-31 2024-08-31 2023-08-31 2022-08-31
Investments - 0.15M 0.00M - -
Net borrowings 0.06M 0.00M 0.00M 0.00M 0.00M
Total cash from financing activities 4.34M 1.08M 0.31M 0.13M 0.40M
Net income -4.00M -2.90M -0.30M -8.47M -0.29M
Change in cash 0.00M -0.06M 0.05M -0.24M 0.12M
Begin period cash flow 0.02M 0.05M 0.01M 0.25M 0.13M
End period cash flow 0.02M 0.02M 0.05M 0.01M 0.25M
Total cash from operating activities -4.32M -1.28M -0.26M -0.37M -0.28M
Issuance of capital stock 4.35M 0.19M 0.00M 0.00M 0.40M
Depreciation 0.01M 0.01M 0.00M - -
Dividends paid - 0.00M 0.00M 0.00M -
Sale purchase of stock -0.08M 0.00M - - -
Capital expenditures 0.02M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.40M 0.96M 0.04M -0.04M 0.00M
Stock based compensation 0.14M 0.53M 0.00M 8.14M 0.00M
Other non cash items 0.31M 0.14M - - -
Free cash flow -4.34M -1.29M -0.26M -0.37M -0.28M

Peer Comparison*

Sector: Industrials Industry: Consulting Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
NORD
Nordicus Partners Corporation Common Stock
-0.13
4.44%
2.80 - - 12107.93 1.18 16971.54
EXPGF
Experian PLC
-
-%
37.51 26.59 19.34 4.43 6.44 4.99
EXPGY
Experian plc PK
-0.97
2.59%
36.53 26.45 19.30 4.41 6.43 4.99
VRSK
Verisk Analytics Inc
1.71
0.85%
202.23 28.72 21.88 7.52 74.89 9.06
EFX
Equifax Inc
0.72
0.41%
177.23 30.32 17.18 3.05 4.62 3.96

Profile*

Nordicus Partners Corporation Common Stock

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.

280 South Beverly Dr, Beverly Hills, CA, United States, 90212

310 666 0750

Name Title Year Born
Mr. Henrik Rouf CEO & President 1968
Mr. Bennett Jay Yankowitz CFO & Director 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…